Track topics on Twitter Track topics that are important to you
Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation articles that have been published worldwide.
We have published hundreds of Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation news stories on BioPortfolio along with dozens of Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation Clinical Trials and PubMed Articles about Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation Companies in our database. You can also find out about relevant Evolution Tricuspid Regurgitation After Repair Degenerative Mitral Regurgitation Drugs and Medications on this site too.
Mitral valve repair (MVr) for severe, degenerative mitral regurgitation (MR) is the gold standard, as medical management carries poor prognosis. However, despite clear benefit of MVr, many eligible patients are untreated. This study investigated whether MVr restores patients to normal life expectancy, at any age of operation, by comparing long-term survival of post-MVr patients to the life expectancy of the general United States (U.S.) population.
To review the efficacy of a minimally invasive surgical technique for mitral valve (MV) repair, we analyze a non-resectional technique for degenerative mitral regurgitation (DMR).
To undertake a systematic review and meta-analysis investigating the short and long-term clinical outcomes of concurrent repair of mild or moderate tricuspid regurgitation during left sided valve surgery.
This study sought to evaluate the effects of the Carillon device on mitral regurgitation severity and left ventricular remodeling.
The main pathophysiological factor of chronic ischemic mitral regurgitation (MR) is the outward displacement of the papillary muscles (PMs) leading to leaflet tethering. For this reason, papillary muscle intervention (PMI) in combination with mitral ring annuloplasty (MRA) has recently been introduced into clinical practice to correct this displacement, and to reduce the recurrence of regurgitation.
This is the third and final part of our update on the latest advances in cardiac valvular replacement. Part 1 was dedicated to cardiac valvular replacement, and Part 2 focused on transcatheter cardiac valvular treatment. This part concerns annuloplasty prostheses for valvular reconstructive surgery. The number of patients undergoing surgical heart valve repair has been increasing, particularly in high-volume centers. Annuloplasty is now considered the gold standard in mitral valve regurgitation repair secon...
Initial studies have suggested the familial clustering of mitral valve prolapse, but most of them were either community based among unselected individuals or applied non-specific diagnostic criteria. Therefore little is known about the familial distribution of mitral regurgitation in a referral-type population with a more severe mitral valve prolapse phenotype. The objective of this study was to evaluate the presence of familial mitral regurgitation in patients undergoing surgery for mitral valve prolapse, ...
The MITRA-FR trial showed that among symptomatic patients with severe secondary mitral regurgitation, percutaneous repair did not reduce the risk of death or hospitalization for heart failure at 12 months compared with guideline-directed medical treatment alone. We report the 24-month outcome from this trial.
The new MitraClip G4 device (Abbott Vascular) has been recently approved by Food and Drug Administration and is currently in limited release. A patient with a large mitral regurgitation (MR) jet but a relatively small mitral valve area (MVA) was not a surgical repair candidate nor an optimal MitraClip third-generation device candidate. Therefore, we implanted the new G4 NTW device that resulted in significant MR reduction with a 57% reduction in MVA. To our knowledge, this is the first reported clinical use...
Left atrial (LA) volumes and function are believed to improve following interventional reduction of mitral regurgitation (MR) with MitraClip. However, exact LA alterations after MitraClip in patients with functional MR and functional mitral regurgitation (FMR) are unknown.
Transcatheter mitral valve repair (TMVr) for the treatment of mitral regurgitation (MR) is a complex procedure that requires development of a unique skillset.
The clinical significance of three-dimensional (3D) vena contracta area (VCA) in tricuspid regurgitation (TR) is not fully elucidated. The aim of this study was to investigate the diagnostic accuracy of 3D VCA using 3D echocardiography-derived regurgitation volume as a reference standard.
This short review article aims to explain the changes in the treatment strategies of interventional care designed to treat secondary mitral valve regurgitation with edge-to-edge repair in comparison to the position paper published in 2013 by the German Society of Cardiology and the German Society of Thoracic and Cardiovascular Surgery. To this end the current data situation with respect to the European Society of Cardiology (ESC) guidelines from 2017, the intraprocedural assessment of mitral valve regurgita...
Resectional and artificial cordal repair techniques are effective strategies for degenerative mitral valve (MV) repair. However, resectional repair requires a tailored approach using various techniques, while cordal repair offers a simpler, easily-reproducible repair. Our approach has evolved from resectional to cordal over time, and we compared outcomes between the eras.
The aim of this study was to compare echocardiographic methods of determining tricuspid regurgitation (TR) severity against TR regurgitant volume (TR) by cardiovascular magnetic resonance (CMR).
Determine the rates, reasons, predictors, and costs of 30-day readmissions following transcatheter mitral valve repair (TMVR) versus surgical mitral valve repair (SMVR) in the United States.
To analyze the current state of the art of functional mitral regurgitation (FMR) treatment.
Screening and early diagnosis of mitral regurgitation (MR) are crucial for preventing irreversible progression of MR. In this study, we developed and validated an artificial intelligence (AI) algorithm for detecting MR using electrocardiography (ECG).
Tricuspid annuloplasty for tricuspid regurgitation (TR) depends on the measurements of tricuspid annular diameter (TAD) obtained in an apical four-chamber view on two-dimensional (2D) transthoracic echocardiography (TTE). We performed a combined 2D and three-dimensional (3D) echocardiographic study to understand the impact of the size, shape, and orientation of a dilated annulus on the inconsistencies between measured 2D TTE-TAD and the actual annular diameter.
Pulmonary hypertension (pHTN) is associated with increased risk of mortality after mitral valve surgery for mitral regurgitation. However, its association with clinical outcomes in patients undergoing transcatheter mitral valve repair (TMVr) with a commercially available system (MitraClip) is unknown.
This study evaluated outcomes of mitral valve surgery for severe ischemic mitral regurgitation (IMR).
Tricuspid regurgitation (TR), particularly functional or secondary TR, is increasingly recognized in clinical practice and when at least moderate in severity is associated with significant increase in mortality. In recent years multiple new trans-catheter devices have been developed to treat tricuspid regurgitation and are now undergoing clinical trial evaluations. The choice of appropriate endpoints in TR trials is particularly challenging as the disease is complex, often co-exists with left heart disease ...
MAVERIC (Mitral Valve Repair Clinical Trial) validates the safety and efficacy of the ARTO system. We here report the first two successful cases of utilizing the ARTO system in patients with symptomatic heart failure (HF) with functional mitral regurgitation (FMR) in Asia.